전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
cetuximab is zo ontwikkeld dat het zich bindt aan de epidermale groeifactorreceptor die wordt aangetroffen op het oppervlak van bepaalde tumorcellen.
cetuximab has been designed to bind to egfr, which can be found on the surface of certain tumour cells.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
perjeta herkent een specifieke plek, de ‘humane epidermale groeifactorreceptor 2’ (her2), en bindt zich daaraan.
perjeta recognises and attaches to a target called “human epidermal growth factor receptor 2” (her2).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
het middel wordt voorgeschreven aan patiënten bij wie sprake is van een mutatie van de kankercellen in de genen die een eiwit aanmaken dat wordt aangeduid als epidermale groeifactorreceptor (egfr).
it is used in patients whose cancer cells have a mutation in the genes that make a protein called epidermal growth factor receptor (egfr).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
olaratumab is een antagonist van uit bloedplaatjes verkregen groeifactorreceptor-α (pdgfr-α) die tot expressie komt op tumor- en stromacellen.
olaratumab is an antagonist of platelet derived growth factor receptor-α (pdgfr-α), expressed on tumour and stromal cells.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
deze bevindingen traden op bij klinisch relevante plasmaconcentraties, waren grotendeels omkeerbaar binnen 4 weken na het beëindigen van de toediening en waren toe te schrijven aan de remming van de vasculaire endotheliale groeifactorreceptor (vegfr) of egfr.
these findings occurred at clinically-relevant plasma concentrations, were largely reversible within 4 weeks of cessation of dosing and were attributable to inhibition of vascular endothelial growth factor receptor (vegfr) or egfr.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
(44-20) 74 18 84 00 fax (44-20) 74 18 84 16 e-mail: mail@emea.europa.eu http://www.emea.europa.eu ©emea 2007 reproduction and/or distribution of this document is authorised for non commercial purposes only provided the emea is acknowledged erlotinib blokkeert de epidermale groeifactorreceptoren die op het oppervlak van bepaalde tumorcellen kunnen voorkomen.
(44-20) 74 18 84 00 fax (44-20) 74 18 84 16 e-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©emea 2007 reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the emea is acknowledged how has tarceva been studied?
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.